24.2. Table 2: Opioid related Mortality, Prescription Opioid Use and Buprenorphine based. MAT 2015. Source: IMSHealth, U
State
Alaska Arizona Maine Nevada Ohio Pennsylvania Tennessee West Virginia
# with Serious Mental Illness in Marketplaces
# with Substance Use Disorder in Marketplaces
Total All Mental Illness and Substance Use Disorders in Marketplace
1,296 7,177 1,277 6,432 13,955 12,853 8,124 3,207
2,754 21,553 8,306 12,864 29,656 51,415 30,466 2,916
5,136 63,344 19,232 22,299 69,255 99,616 78,807 9,682
# with Mental Illness and Substance Use Disorder conditions in Medicaid Expansion 5,389 15,400 NA 28,080 151,257 80,910 NA 22,576
Total BH (Columns 4 + 5)
10,525 78,744 19,232 50,379 220,512 180,526 78,807 32,358
Table 1: People with Behavioral Health Needs in Exchanges and Expansion Population 2016
State Alaska Arizona Maine Nevada Ohio Pennsylvania Tennessee West Virginia U.S.
Drug Overdose Deaths (rate/100,000) 122 (16.0) 1,274 (19.0) 269 (21.2) 619 (20.4) 3,310 (29.9) 3,264 (26.3) 1,457 (22.2) 725 (41.5) 52,404 (16.3)
Rx Opioid Use per 1000 population 566 693 705 816 828 795 1,161 1,049 695
Buprenorphine use per 1000 population 30 19 114 24 69 75 118 158 39
% Share of Bupe paid by Medicaid 34.2% 14.9 37.8 11.9 49.5 29.2 10.0 44.7 24.2
Table 2: Opioid related Mortality, Prescription Opioid Use and Buprenorphine based MAT 2015 Source: IMSHealth, Use of Opioid Recovery Medications Recent Evidence on State Level
Buprenorphine Use and Payment Types, September, 2016 and CDC Mortality Data Tabulations; Mortality rates are age adjusted
Health Insurance Marketplaces Medicaid Expansion
Behavioral Health Care Service Users 554,488
Dollars
1,286,550
$4.5 billion
$981 million
Table 3: U.S. Reductions in covered users of behavioral health care and spending covered by insurance programs
